| Aug 7 |
ANI Pharmaceuticals, Inc. Announces Proposed Convertible Senior Notes Offering
|
| Aug 6 |
Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics
|
| Aug 6 |
ANI Pharmaceuticals (ANIP) Tops Q2 Earnings and Revenue Estimates
|
| Aug 6 |
ANI: Q2 Earnings Snapshot
|
| Aug 6 |
ANI Pharmaceuticals beats top-line and bottom-line estimates; raises FY24 outlook
|
| Aug 6 |
ANI Pharmaceuticals Reports Second Quarter 2024 Financial Results and Raises 2024 Guidance
|
| Aug 5 |
ANI Pharmaceuticals Q2 2024 Earnings Preview
|
| Aug 5 |
Seeking Clues to ANI (ANIP) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
|
| Aug 2 |
ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028
|
| Jul 31 |
ANI Pharmaceuticals to Discuss Second Quarter 2024 Financial Results on August 6, 2024, at 8:30 a.m. ET
|
